Design, synthesis, conformational analysis and biological activities of purine-based 1,2-di-substituted carbocyclic nucleosides

Chemical and Pharmaceutical Bulletin

Volumn 48, Issue 2, 2000, Pages 293-295

  Teran, Carmen ^a   Santana, Lourdes ^b   Teijeira, Marta ^b   Uriarte, Eugenio ^b   De Clercq, Erik ^c  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

AM1 semiempirical method; Antitumor agent; Antiviral agent; Carbonucleosides; Purine derivative

Indexed keywords

6 CHLORO 9 [2 (HYDROXYMETHYL)CYCLOPENTYL] 9H PURINE; CARBOCYCLIC NUCLEOSIDE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

EID: 0034011870     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.48.293     Document Type: Article

References (18)

1. Hobbs J. B., "Purine and Pyrimidine Targets," in Comprehensive Medicinal chemistry, Vol. 2, ed. by Hansch C., Pergamon Press, Ch., 1990, pp. 299-332.
2. De Clercq E., J. Med. Virol., 5, 149-164 (1995).
3. Mansour T. S., Storer R., Current Pharmaceutical Design, 3, 227-264 (1997).
4. a) De Clercq E., Clinical Microbiology Reviews, 10, 674-693 (1997):
5. b) Idem, The Medical Letter, 1998, 5-10.
6. Marquez V. E., Advances in Antiviral Drug Design, 2, 89-146 (1996).
7. Shealy Y. F., Clayton J. D., J. Am. Chem. Soc., 88, 3885-3887 (1966).
8. Vince R., Hua M., J. Med. Chem., 33, 17-21, (1990).
9. Santana L., Teijeira M., Uriarte E., De Clercq E., Balzarini J., Nucleosides & Nucleotides, 14, 521-523, (1995); Santana L., Teijeira M., Uriarte E., Fadda A., Podda G., Catinella S., Traldi P., Rapid Commun. Mass Spectrom., 1996, 1316-1319.
10. Santana L., Teijeira M., Uriarte E., De Clercq E., Balzarini J., Nucleosides & Nucleotides, 14, 521-523, (1995); Santana L., Teijeira M., Uriarte E., Fadda A., Podda G., Catinella S., Traldi P., Rapid Commun. Mass Spectrom., 1996, 1316-1319.
11. Saenger W., "Principles of Nucleic Acid Structure," Springer-Verlag, New York, Inc., New York, 1984.
12. Herdewyn P., Balzarini J., De Clercq E., "Advances in Antiviral Drug Design," Vol. 1, ed. by De Clercq E., JAI Press, Inc., Greenwich, CT, 1993, pp. 233-318.
13. Santana L., Teijeira M., Terán C., Uriarte E., Casselato U., Graziani R., Nucleosides & Nucleotides, 15, 1179-1187 (1996).
14. Teijeira M., Doctoral Thesis, University of Santiago de Compostela, Spain, 1996.
15. Teijeira M., Santana L., Uriarte E., Magn. Reson. Chem., 35, 806-807 (1997).
16. Dewar M. J. S., Zoebisch E. G., Healy E. F., Stewart J. J. P., J. Am. Chem. Soc., 107, 3902-3909 (1985).
17. BIOSYM Technologies, Inc., 10065 Barnes Canyon Road, San Diego, CA 92121.
18. De Clercq E., "In vitro and ex vivo test systems to rationalize drug design and delivery," ed. by Crommelin D., Couvreur P., Duchene D., Editions de Santé, Paris, 1994, pp. 108-125.